Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ARAridis Pharmaceuticals, Inc. logo

Aridis Pharmaceuticals, Inc. (ARDS)

Other OTC · Currency in USD
$0.00 ▲ +0.00 (+100.00%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $0.05
Volume
10
Avg. Volume
14,527
Market Cap
$8.92K
Beta (5Y Monthly)
0.76
PE Ratio (TTM)
--
EPS (TTM)
-$1.64
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Aridis Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
37
CEO
Vu L. Truong

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin. Also in their pipeline is AR-320, another fully human IgG1 monoclonal antibody designed to target S. aureus alpha toxin, aiming to treat infections stemming from both methicillin-resistant (MRSA) and methicillin-susceptible S. aureus.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate -$0.60 · Revenue est. $266.67K
DateEst.Actual
Nov 3, 2023-$0.10-$0.02Beat
Sep 13, 2023–$0.33

Analyst view

Rating: Buy
Buy 86% · Hold 14% · Sell 0%

Get free alerts on ARDS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.